ABSCIENCES (EPA:AB) | Finanzwire

BRIEF

published on 12/17/2024 at 19:09, 3 days 18 hours ago

AB Science presents the advances of AB8939 for acute myeloid leukemia

Phase 1 AB8939 Acute Myeloid Leukemia Drug Resistance Potential Market
PRESS RELEASE

published on 12/17/2024 at 19:04, 3 days 18 hours ago

AB Science provides a summary of the webcast held on December 16, 2024
AB Science provides an update on AB8939, a novel microtubule destabilizer and ALDH inhibitor in phase 1 for AML treatment. Potential market size exceeded EUR 2 billion per annum

Market Potential AML Treatment AB Science Phase 1 AB8939
BRIEF

published on 10/17/2024 at 19:33, 2 months 3 days ago

AB Science Faces Setback in EMA Approval for ALS Treatment

AB Science Masitinib Marketing Authorization ALS Treatment EMA Decision
PRESS RELEASE

published on 10/17/2024 at 19:28, 2 months 3 days ago

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
AB Science provides an update on the application for conditional marketing authorisation of masitinib in the treatment of amyotrophic lateral sclerosis. EMA confirms negative opinion but company remains focused on confirmatory phase 3 program

Phase 3 Program AB Science Masitinib Amyotrophic Lateral Sclerosis Conditional Marketing Authorisation
BRIEF

published on 10/10/2024 at 08:32, 2 months 11 days ago

AB Science Reports Mid-2024 Financial Results and Clinical Developments

Financial Results Clinical Trials Capital Increase AB Science Masitinib
PRESS RELEASE

published on 10/10/2024 at 08:27, 2 months 11 days ago

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities
AB Science presents financial results for the first half of 2024, updates on clinical development in ALS and MS, positive results in Covid-19 study, and intellectual property strengthening. AB announces capital increase and coverage initiations. Press Release by AB Science SA

Financial Results Capital Increase Clinical Development Intellectual Property AB Science
BRIEF

published on 09/30/2024 at 08:34, 2 months 21 days ago

AB Science announces a capital increase of 5.0 million euros

Capital Increase Clinical Development AB Science Masitinib European Investors
BRIEF

published on 09/23/2024 at 17:56, 2 months 27 days ago

AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis

Multiple Sclerosis Treatment Masitinib ECTRIMS 2024 Neurodegenerative
PRESS RELEASE

published on 09/23/2024 at 17:51, 2 months 27 days ago

AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024, showing promising results in phase 2B/3 study AB07002

Phase 3 Study AB Science Masitinib ECTRIMS 2024 Progressive Multiple Sclerosis
BRIEF

published on 07/08/2024 at 08:01, 5 months 13 days ago

AB Science Announces Positive Results of Phase 2 Study for Masitinib in COVID-19

COVID-19 Clinical Trial Phase 2 Study AB Science Masitinib

Published on 12/21/2024 at 01:30, 12 hours 7 minutes ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 12 hours 7 minutes ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 13 hours 32 minutes ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 13 hours 37 minutes ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 14 hours 7 minutes ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

Published on 12/21/2024 at 00:51, 12 hours 45 minutes ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 12 hours 51 minutes ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 18 hours 26 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 18 hours 40 minutes ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 19 hours 36 minutes ago

ARYZTA AG Announces New Board Technology Committee

View all EQS

Published on 12/21/2024 at 12:17, 1 hour 19 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 19 hours 37 minutes ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 19 hours 42 minutes ago

Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 23 hours 37 minutes ago

Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 1 day 19 hours ago

Share capital decrease by way of treasury shares cancellation

View all LES ECHOS COMFI WIRE

News